Roellig, C. and Serve, H. and Huettmann, A. and Noppeney, R. and Mueller-Tidow, C. and Krug, U. and Baldus, C. D. and Brandts, C. H. and Kunzmann, V and Einsele, H. and Kraemer, A. and Schaefer-Eckart, K. and Neubauer, A. and Burchert, A. and Giagounidis, A. and Krause, S. W. and Mackensen, A. and Aulitzky, W. and Herbst, R. and Haenel, M. and Kiani, A. and Frickhofen, N. and Kullmer, J. and Kaiser, U. and Link, H. and Geer, T. and Reichle, A. and Junghanss, C. and Bornhaeuser, M. and Schaich, M. and Thiede, C. and Schetelig, J. and Kramer, M. and Berdel, W. E. and Ehninger, G.
(2018)
The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up of the randomized-controlled SORAML trial.
ONCOLOGY RESEARCH AND TREATMENT, 41 (suppl4).
p. 9.
ISSN 2296-5270, 2296-5262
Full text not available from this repository.
Actions (login required)
 |
View Item |
